GILD catalyst calendar

GILEAD SCIENCES, INC.

Upcoming catalysts
19
Cash runway
Cash generating
Phase 3 programs
54

GILEAD SCIENCES, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 1, 2026, a projected date rather than a confirmed one. There are 19 upcoming events on record.

GILEAD SCIENCES, INC. generates cash from operations, so a burn-based runway figure does not apply.

Across 285 concluded trials, 79% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 1, 2026 est. Next quarterly earnings (projected) Earnings —
February 15, 2027 Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) Trial Milestone Phase 1
August 15, 2027 Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels Trial Milestone Phase 2
August 15, 2027 A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 Trial Milestone Phase 2
December 15, 2027 Study With Various Immunotherapy Treatments in Participants With Lung Cancer Trial Milestone Phase 2
January 15, 2028 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Trial Milestone Phase 2/Phase 3
March 15, 2028 Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer Trial Milestone Phase 1/Phase 2
May 15, 2028 Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors Trial Milestone Phase 1
September 15, 2028 Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) Trial Milestone Phase 3
December 15, 2028 Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer Trial Milestone Phase 2
January 15, 2029 Study of GS-2426 in Participants With Advanced Solid Tumors Trial Milestone Phase 1
March 15, 2029 Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Trial Milestone Phase 3
March 15, 2029 Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Trial Milestone Phase 3
August 15, 2029 Study of GS-0415 and How It Works in People With HIV Trial Milestone Phase 1
September 15, 2029 A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors Trial Milestone Phase 1
October 15, 2029 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Trial Milestone Phase 3
April 15, 2030 Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Trial Milestone Phase 2
August 15, 2030 Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis Trial Milestone Phase 3
March 15, 2034 A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Trial Milestone Phase 4

Track GILD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open GILD in the tracker

Recent history

DateEventTypePhase
August 4, 2026 Quarterly results filed (8-K) Earnings —
July 27, 2026 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) Trial Milestone Phase 2
May 20, 2026 8-K filed: Material agreement, Other event Corporate —
May 11, 2026 Study of GS-0272 in Participants With Rheumatoid Arthritis Trial Milestone Phase 1
May 7, 2026 Quarterly results filed (8-K) Earnings —
May 6, 2026 Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) Trial Milestone Phase 3
April 28, 2026 8-K filed: Reg FD disclosure, Other event Filing —
April 23, 2026 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 Trial Milestone Phase 3
April 17, 2026 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 Trial Milestone Phase 3
March 16, 2026 Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Trial Milestone Phase 2/Phase 3
March 4, 2026 Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis Trial Milestone Phase 2
March 3, 2026 Study of GS-3242 in Participants With HIV-1; Substudy-05 Trial Milestone Phase 1
February 23, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
February 10, 2026 Quarterly results filed (8-K) Earnings —
November 19, 2025 8-K filed: Leadership change Corporate —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 6, 2025 8-K filed: Reg FD disclosure Filing —
September 19, 2025 Study of GS-1219 in Participants With HIV-1 Trial Milestone Phase 1
August 14, 2025 8-K filed: Leadership change Corporate —
August 7, 2025 Quarterly results filed (8-K) Earnings —
July 4, 2025 Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Trial Milestone Phase 3
June 16, 2025 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Trial Milestone Phase 1
April 24, 2025 Quarterly results filed (8-K) Earnings —
March 24, 2025 Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 Trial Milestone Phase 2/Phase 3
February 24, 2025 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Trial Milestone Phase 1
January 29, 2025 Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) Trial Milestone Phase 4
January 16, 2025 Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women Trial Milestone Phase 2
January 15, 2025 Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B Trial Milestone Phase 1
November 12, 2024 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Trial Milestone Phase 2
October 18, 2024 Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy Trial Milestone Phase 4

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.